- Recruiting
NCT04776018: Phase 1/2: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In RRMM
Updated: Sep 2, 2022
NCT04776018: Phase 1/2: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies (mAbs) to treat participants who have relapsed or refractory multiple myeloma (RRMM).
The main aims of the study are to evaluate the safety and efficacy of TAK-981 in combination with anti-CD38 (mAbs) and to determine the recommended Phase 2 dose (RP2D).
Participants will be on this combination treatment for 28-day cycles. They will continue with this treatment until disease progression or unacceptable toxicity.
Sponsor
Takeda
Multiple locations
ClinicalTrials.gov Identifier: NCT04776018
Official Title: A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
First Posted : March 1, 2021
Click here to see details on ClinicalTrials.gov
TAK-981-1503
Drug: TAK-981
Drug: Mezagitamab
Drug: Daratumumab and Hyaluronidase-fihj
Subasumstat (Code C156270)
Subasumstat
SUBASUMSTAT
TAK 981
TAK-981
TAK981
Mezagitamab (Code C148078)
Anti-CD38 MAb TAK-079
Mezagitamab
MEZAGITAMAB
TAK 079
TAK-079
TAK079
Locations
United States, Arizona
United States, Florida
United States, Georgia
United States, Indiana
United States, Maryland
United States, Minnesota
United States, Nebraska
United States, New York
United States, Ohio
United States, Texas
United States, Wisconsin